Skip to main content Skip to search Skip to main navigation

ICH: Assembly Meeting 2025

The International Council for Harmonisation (ICH) held its Assembly meeting on 13–14 May 2025 in Madrid, Spain, alongside 11 Working Groups and prior meetings of the Management and MedDRA Steering Committees.

Membership Updates
ICH welcomed three new Observers: DINAVISA (Paraguay), MOH (Kuwait), and SRS (El Salvador), bringing the total to 23 Members and 41 Observers. Mr. Daisuke Koga (MHLW/PMDA, Japan) was elected as the new Vice-Chair of the ICH Management Committee.

New Harmonisation Topics
Four new topics were adopted for future guideline development:

  • Use of Real-World Evidence for regulatory decisions
  • Utility of Comparative Efficacy Studies in biosimilar development
  • Natural History Studies and Registry Data in rare disease drug development
  • Comparability of ATMPs following manufacturing changes (Annex to ICH Q5E)

Guideline Progress and Milestones
The Assembly acknowledged progress on several guidelines:

  • Finalised (Step 4):
    • ICH E6(R3): Revised “Good Clinical Practice” guideline adopted in January 2025
  • New Drafts Endorsed (Step 2):
    • ICH M4Q(R2): Updated Common Technical Document (CTD) for pharmaceutical registration.
    • ICH E21: Inclusion of pregnant and breastfeeding individuals in clinical trials.
    • ICH Q1: Stability testing of drug substances and products.
    • ICH M13B: Biowaivers for additional strengths of immediate-release solid oral dosage forms in bioequivalence studies
    • ICH M11: Updated Technical Specification for the electronic protocol standard (CESHARP).
    • ICH M7 Addendum: Framework for assessment and control of DNA-reactive impurities, including nitrosamines.

MedDRA Updates
New MedDRA Steering Committee appointments: NMPA (China), SFDA (Saudi Arabia), and IFPMA (Standing Observer). MedDRA is now used by over 9,000 organizations in 141 countries and available in 24 languages, including Icelandic. The MedDRA LMS, launched in early 2025, offers structured online training.

Next Meeting
The next ICH Assembly will take place on 18–19 November 2025 in Singapore.


Source:

ICH: Press Release


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Microbiological Monitoring – Sources of Contamination

Microbiological Monitoring – Sources of Contamination

All pharmaceutical dosage forms must be manufactured under controlled microbiological conditions. This requires microbial monitoring. This applies not only to sterile manufacturing, but also to facilities that manufacture non-sterile products.
Read more
What are the Prospects and Developments in the Operation of Computerised Systems?

What are the Prospects and Developments in the Operation of Computerised Systems?

Here's the answer:
Read more
Switzerland: Updated MRA with the EU to Ease Market Access of Medical Devices

Switzerland: Updated MRA with the EU to Ease Market Access of Medical Devices

MedTech Europe and partner associations welcomed the EU–Switzerland agreement package, including the long-awaited update of the Mutual Recognition Agreement (MRA).
Read more
FDA: Draft Guidance on Responding to Form 483 Observations

FDA: Draft Guidance on Responding to Form 483 Observations

The US Food and Drug Administration (FDA) has issued a draft guidance on responding to Form FDA-483 observations following drug CGMP inspections. The document provides recommendations on how manufacturers should structure their responses and what information they should include.
Read more
Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Which Quality and Process Parameters must Typically be Taken into Account During Process Validation for Terminally Sterilized Products?

Here's the answer:
Read more
Veterinary GMP 2026: The New Regulatory Framework

Veterinary GMP 2026: The New Regulatory Framework

Implementing Regulations (EU) 2025/2091 and 2025/2154 consolidate the GMP requirements for veterinary medicinal products into a distinct and legally binding framework for the first time. While establishing regulatory independence for the veterinary sector, they remain substantively aligned with the EU GMP Guide.
Read more
Previous
Next